Manushka V. Vaidya1, Donghyun Hong1, Sule Sahin1, Georgios Batsios1, Pavithra Viswanath1, Sabrina M. Ronen1, and Peder E.Z. Larson1
1Department of Radiology, University of California San Francisco, San Francisco, CA, United States
Synopsis
We
introduce a kinetic modeling framework to detect glutamate and
2-hydroxyglutarate (2HG) production from hyperpolarized
[1-13C]alpha-ketoglutarate (C1aKG). Detection of 2HG in vivo is often
confounded with [5-13C]alpha-ketoglutarate (C5aKG), a natural abundance peak.
We employ the model, based on the solution to differential equations of a
three-site model, to separately detect 2HG from C5aKG. To test the model, we
used cell lysate data where separate signal peaks of 2HG and C5aKG were
experimentally measured. Cases with inputs of 2HG alone, 2HG+C5aKG, and C5aKG
alone were evaluated to validate the model.
PURPOSE:
Metabolic conversion
of hyperpolarized [1-13C] alpha-ketoglutarate (C1aKG) to 2-hydroxyglutarate
(2HG) is useful for detecting mutant isocitrate dehydrogenase 1 (IDH1) status
of low grade gliomas (1). Changes in flux of C1aKG to glutamate and 2HG can be
used as markers for response to treatment (2). The detected spectrum of 2HG production is often
contaminated with [5-13C] alpha-ketoglutarate (C5aKG), which is
naturally occurring in the C1aKG substrate. The similar chemical shifts of 2HG
and C5aKG, both approximately at 184 ppm, make it difficult to detect and
quantify the production of 2HG in vivo (1). In this work, we apply a kinetic modeling
framework to separate the product from C5aKG and quantify conversion to 2HG. We
also compute the metabolic conversion rates of aKG to 2HG (kaKG-2HG)
and glutamate (kaKG-Glu), which could be used to monitor treatment
response and aggressiveness of the tumor. METHODS:
Kinetic
model: For the three-site model shown in Fig 1, a kinetic model (3) was adapted
to quantify magnetization of products, namely 2HG and glutamate, and determine
the metabolic conversion rates. The estimated product magnetization at each
time point was simulated based on the measured substrate magnetization at
adjacent timepoints and the estimated product magnetization at the previous
time point. The fitted values were solved based on a minimization of the
least-squares error between the measured and the estimated product
magnetization using a constrained, nonlinear least-squares solver in MATLAB. To
separate 2HG from the C5aKG, individual metabolites were first estimated based
on the solution to the differential equations (Fig 2), which include estimated
and fixed parameters: T1 values, flip angles, C1aKG to C5aKG ratio,
TR, starting magnetization values, and metabolic conversion rates. The added
signal of simulated 2HG and C5aKG was then fitted to the measured product
magnetization by iteratively adjusting estimated parameters.
Cell
lysate data: To validate the overlapped fitting method,
we used cell lysate data (2). Greater
B0 homogeneity for cell lysates and chemical shift at the high field
strength allowed for detection of separate product peaks of 2HG and C5aKG. 13C
spectra were acquired using an 11.7 T spectrometer (Agilent Technologies, USA)
with flipangle = 13°, TR = 3s, scans = 100. The data was normalized to the cell
number and the maximum substrate signal. The following cases were evaluated:
Overlapped
fitting method: computes separate fits of both 2HG
and C5aKG for the following inputs.
1) 2HG +
C5aKG
2) C5aKG with
no 2HG
Conventional
fitting method: computes the fit of a product from
the experimentally measured product signal.
1) 2HG alone
2) Glutamate
RESULTS:
For
the overlapped fitting method, the model was able to detect 2HG separately from the
combined input (Fig 3C). Lower 2HG was detected for an input of C5aKG alone
(Fig 3D), although no detection of 2HG would be expected for this case. The case
where 2HG alone was used as input, with the conventional fitting method (Fig 4B),
provided the best fit and consistent kinetic rates (Table 1). This served as
the ground truth for other computations.DISCUSSION and CONCLUSIONS:
Our work demonstrates the feasibility of quantifying
products and metabolic conversion rates of glutamate and 2HG production from
C1aKG. In particular, the kinetic model was able to detect 2HG from naturally
occurring C5aKG. Cell lysate data, which contained distinguishable signal peaks
of all products, were used to test whether the model could detect the presence
or absence of 2HG from an input of either C5aKG+2HG or C5aKG alone. Although
the computed 2HG values reduced when measured signal of C5aKG alone was used as
input, the model overestimated 2HG for most datasets. Consistent values of kaKG-2HG
for the first three datasets, and
low RMSE values for all datasets for the case when 2HG alone was used as input,
suggested that the model performed well when using the conventional fitting
method. While this served as a ground truth for other cases, 2HG measured
signal cannot be distinguished from naturally occurring C5aKG in vivo
based on ratio between C1aKG and C5aKG alone. In particular, using metabolite-specific,
variable flip angle scheme in vivo to
improve SNR (4) can differentially deplete magnetization for the various
metabolites and 13C locations, which could make the fitting more
challenging. Future work includes modifying estimated parameters and
assumptions in the model to fully optimize the kinetic model, and implementing
the model for data acquired in vivo. Acknowledgements
This
work was supported by NIH Training Grant T32CA151022 and American Cancer Society Research Scholar
Grant 18-005-01-CCEReferences
1.
Chaumeil MM, Larson PEZ, Yoshihara HAI, Danforth OM, Vigneron DB, Nelson SJ,
Pieper RO, Philips JJ, Ronen SM. Non-invasive in vivo assessment of IDH1
mutational status in glioma. Nat. Commun. 2013; 4:2429.
2.
Molloy AR, Najac C, Viswanath P, Lakhani A, Subramani E, Batsios G, Radoul M,
Gillespie AM, Pieper RO, Ronen SM. MR-detectable metabolic biomarkers of
response to mutant IDH inhibition in low-grade glioma. Theranostics 2020; 10:19.
3.
Larson PEZ, Chen HY, Gordon JW, Korn N, Maidens J, Arcak M, Tang S, Criekinge
M, Carvajal L, Mammoli D, Bok R, Aggarwal R, Ferrone M, Slater JB, Nelson SJ,
Kurhanewicz J, Vigneron DB. Investigation of analysis methods for
hyperpolarized 13C-pyruvate metabolic MRI in prostate cancer patients. NMR
Biomed. 2018; 31:11.
4. Hong D, Batsios G, Viswanath P, Gillespie
AM, Vaidya M, Larson PEZ, Ronen SM. Acquisition and quantification pipeline for
in vivo hyperpolarized 13C magnetic resonance spectroscopy. In preparation,
2020.